The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Open accessAbstract
BACKGROUND: Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa. We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML. METHODS: We randomly assigned 1106 patients to receive imatinib (553 patients) or interferon alfa plus low-dose cytarabine (553 patients). Crossover to the alternative group was allowed if stringent criteria defining treatment failure or intolerance were met. Patients were evaluated for hematologic and cytogenetic responses, toxic effects, and rates of progression. RESULTS: After a median follow-up of 19 months, the estimated rate of a major cytogenetic response (0 to 35 percent of cells in metaphase positive for the Philadelphia chromosome) at 18 months was 87.1 percent (95 percent confidence interval, 84.1 to 90.0) in the imatinib group and 34.7 percent (95 percent confidence interval, 29.3 to 40.0) in the group given interferon alfa plus cytarabine (P<0.001). The estimated rates of complete cytogenetic response were 76.2 percent (95 percent confidence interval, 72.5 to 79.9) and 14.5 percent (95 percent confidence interval, 10.5 to 18.5), respectively (P<0.001). At 18 months, the estimated rate of freedom from progression to accelerated-phase or blast-crisis CML was 96.7 percent in the imatinib group and 91.5 percent in the combination-therapy group (P<0.001). Imatinib was better tolerated than combination therapy. CONCLUSIONS: In terms of hematologic and cytogenetic responses, tolerability, and the likelihood of progression to accelerated-phase or blast-crisis CML, imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationA minute chromosome in human chronic granulocytic leukemia
Nowell̀, P. C. (1960) · Science · Cited by 2,269
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Self-citationStructural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Cited by
Items 101–173 of 173
Schuh, A., Becq, J., Humphray, S., Alexa, A., Burns, A., Clifford, R., Feller, S. M., Grocock, R., Henderson, S., Khrebtukova, I., et al. (2012) · Blood · doi:10.1182/blood-2012-05-433540 · Cited by 322
Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate
Berman, E., Nicolaides, M., Maki, R. G., Fleisher, M., Chanel, S., Scheu, K., Wilson, B.-A., Heller, G., & Sauter, N. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051140 · Cited by 319
Moving treatment-free remission into mainstream clinical practice in CML
Hughes, T. P., & Ross, D. M. (2016) · Blood · doi:10.1182/blood-2016-01-694265 · Cited by 317
Self-citationRea, D., Nicolini, F. E., Tulliez, M., Guilhot, F., Guilhot, J., Guerci-Bresler, A., Gardembas, M., Coiteux, V., Guillerm, G., Legros, L., et al. (2017) · Blood · doi:10.1182/blood-2016-09-742205 · Cited by 317
Self-citationThe chronic myeloid leukemia stem cell: stemming the tide of persistence
Holyoake, T. L., & Vetrie, D. (2017) · Blood · doi:10.1182/blood-2016-09-696013 · Cited by 314
Burgess, M. R., Skaggs, B. J., Shah, N. P., Lee, F. Y., & Sawyers, C. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409770102 · Cited by 313
A Survey of the Structures of US FDA Approved Combination Drugs
Das, P., Delost, M. D., Qureshi, M. H., Smith, D. T., & Njardarson, J. T. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01610 · Cited by 312
Intensive care of the cancer patient: recent achievements and remaining challenges
Azoulay, E., Soares, M., Darmon, M., Benoit, D., Pastores, S., & Afessa, B. (2011) · Annals of Intensive Care · doi:10.1186/2110-5820-1-5 · Cited by 311
An, X., Tiwari, A. K., Sun, Y., Ding, P.-R., Ashby, C. R., & Chen, Z.-S. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.04.016 · Cited by 309
Pfirrmann, M., Baccarani, M., Saussele, S., Guilhot, J., Cervantes, F., Ossenkoppele, G., Hoffmann, V. S., Castagnetti, F., Hasford, J., Hehlmann, R., et al. (2016) · Leukemia · doi:10.1038/leu.2015.261 · Cited by 307
Self-citationIntegration of EGFR inhibitors with radiochemotherapy
Nyati, M. K., Morgan, M. A., Feng, F. Y., & Lawrence, T. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1953 · Cited by 304
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Jänne, P. A., Gray, N., & Settleman, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2871 · Cited by 303
A comprehensive review of protein kinase inhibitors for cancer therapy
Kannaiyan, R., & Mahadevan, D. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1527688 · Cited by 302
Azoulay, É., Mokart, D., Lambert, J., Lemiale, V., Rabbat, A., Kouatchet, A., Vincent, F., Gruson, D., Bruneel, F., Epinette-Branche, G., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0018oc · Cited by 300
Genomics and the Continuum of Cancer Care
McDermott, U., Downing, J. R., & Stratton, M. R. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0907178 · Cited by 299
Organic Cation Transporters in Health and Disease
Koepsell, H. (2020) · Pharmacological Reviews · doi:10.1124/pr.118.015578 · Cited by 297
Aichberger, K. J., Herndlhofer, S., Schernthaner, G., Schillinger, M., Mitterbauer‐Hohendanner, G., Sillaber, C., & Valent, P. (2011) · American Journal of Hematology · doi:10.1002/ajh.22037 · Cited by 296
le Coutre, P., Ottmann, O. G., Giles, F., Kim, D.-W., Cortes, J., Gattermann, N., Apperley, J. F., Larson, R. A., Abruzzese, E., O'Brien, S. G., et al. (2008) · Blood · doi:10.1182/blood-2007-04-083196 · Cited by 294
Self-citationGaynon, P. S., Angiolillo, A. L., Carroll, W. L., Nachman, J. B., Trigg, M. E., Sather, H. N., Hunger, S. P., Devidas, M., & for the Children's Oncology Group, A. C. (2010) · Leukemia · doi:10.1038/leu.2009.262 · Cited by 293
Sant, M., Minicozzi, P., Mounier, M., Anderson, L. A., Brenner, H., Holleczek, B., Marcos-Gragera, R., Maynadié, M., Monnereau, A., Osca-Gelis, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70282-7 · Cited by 291
Targeted Therapies for Cancer 2004
Ross, J. S., Schenkein, D. P., Pietrusko, R. G., Rolfe, M., Linette, G. P., Stec, J. J., Stagliano, N. E., Ginsburg, G. S., Symmans, W. F., Pusztai, L., et al. (2004) · American Journal of Clinical Pathology · doi:10.1309/5cwp-u41a-fr1v-ym3f · Cited by 286
Cortes, J. E., Baccarani, M., Guilhot, F., Druker, B. J., Branford, S., Kim, D.-W., Pane, F., Pasquini, R., Goldberg, S. L., Kalaycio, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3724 · Cited by 284
Self-citationCardiotoxicity induced by tyrosine kinase inhibitors
Orphanos, G. S., Ioannidis, G. N., & Ardavanis, A. G. (2009) · Acta Oncologica · doi:10.1080/02841860903229124 · Cited by 284
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring
Jabbour, E., & Kantarjian, H. (2022) · American Journal of Hematology · doi:10.1002/ajh.26642 · Cited by 281
Self-citationLipkovich, I., Dmitrienko, A., Denne, J., & Enas, G. (2011) · Statistics in Medicine · doi:10.1002/sim.4289 · Cited by 281
Discontinuation of imatinib therapy after achieving a molecular response
Cortes, J., O'Brien, S., & Kantarjian, H. (2004) · Blood · doi:10.1182/blood-2004-04-1335 · Cited by 280
Self-citationHotte, S. J., Winquist, E. W., Lamont, E., MacKenzie, M., Vokes, E., Chen, E. X., Brown, S., Pond, G. R., Murgo, A., & Siu, L. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.125 · Cited by 278
Kalmanti, L., Saussele, S., Lauseker, M., Müller, M. C., Dietz, C. T., Heinrich, L., Hanfstein, B., Proetel, U., Fabarius, A., Krause, S. W., et al. (2015) · Leukemia · doi:10.1038/leu.2015.36 · Cited by 277
Self-citationCilloni, D., & Saglio, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1613 · Cited by 274
Self-citationMechanism-based cancer therapy: resistance to therapy, therapy for resistance
Ramos, P., & Bentires-Alj, M. (2015) · Oncogene · doi:10.1038/onc.2014.314 · Cited by 272
DeAngelo, D. J., Stone, R. M., Heaney, M. L., Nimer, S. D., Paquette, R. L., Klisovic, R. B., Caligiuri, M. A., Cooper, M. R., Lecerf, J.-M., Karol, M. D., et al. (2006) · Blood · doi:10.1182/blood-2006-02-005702 · Cited by 272
Self-citationCasali, P. G., Messina, A., Stacchiotti, S., Tamborini, E., Crippa, F., Gronchi, A., Orlandi, R., Ripamonti, C., Spreafico, C., Bertieri, R., et al. (2004) · Cancer · doi:10.1002/cncr.20618 · Cited by 268
Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Assouline, S., Etienne, G., Nicolini, F. E., le Coutre, P., Clark, R. E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00080-2 · Cited by 265
Self-citationHuang, M.-J., Cheng, Y.-C., Liu, C.-R., Lin, S., & Liu, H. E. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.06.019 · Cited by 259
Efficace, F., Baccarani, M., Breccia, M., Alimena, G., Rosti, G., Cottone, F., Deliliers, G. L., Baratè, C., Rossi, A. R., Fioritoni, G., et al. (2011) · Blood · doi:10.1182/blood-2011-04-347575 · Cited by 257
Self-citationImatinib (STI571)-Mediated Changes in Glucose Metabolism in Human Leukemia BCR-ABL-Positive Cells
Gottschalk, S., Anderson, N., Hainz, C., Eckhardt, S. G., & Serkova, N. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0039 · Cited by 256
New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance
Kantarjian, H. M., Talpaz, M., Giles, F., O'Brien, S., & Cortes, J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-12-200612190-00008 · Cited by 256
Self-citationZhang, B., Strauss, A. C., Chu, S., Li, M., Ho, Y., Shiang, K.-D., Snyder, D. S., Huettner, C. S., Shultz, L., Holyoake, T., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.011 · Cited by 256
Hoffmann, V. S., Baccarani, M., Hasford, J., Lindoerfer, D., Burgstaller, S., Sertic, D., Costeas, P., Mayer, J., Indrak, K., Everaus, H., et al. (2015) · Leukemia · doi:10.1038/leu.2015.73 · Cited by 256
Self-citationOncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Pagliarini, R., Shao, W., & Sellers, W. R. (2015) · EMBO reports · doi:10.15252/embr.201439949 · Cited by 253
Aichberger, K. J., Mayerhofer, M., Krauth, M.-T., Skvara, H., Florian, S., Sonneck, K., Akgul, C., Derdak, S., Pickl, W. F., Wacheck, V., et al. (2005) · Blood · doi:10.1182/blood-2004-02-0749 · Cited by 253
Hexner, E. O., Serdikoff, C., Jan, M., Swider, C. R., Robinson, C., Yang, S., Angeles, T., Emerson, S. G., Carroll, M., Ruggeri, B., et al. (2008) · Blood · doi:10.1182/blood-2007-04-083402 · Cited by 252
Fluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity
Yu, Y., Liu, A., Dhawan, G., Mei, H., Zhang, W., Izawa, K., Soloshonok, V. A., & Han, J. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.05.042 · Cited by 182
Warfvinge, R., Geironson, L., Sommarin, M. N. E., Lang, S., Karlsson, C., Roschupkina, T., Stenke, L., Stentoft, J., Olsson-Strömberg, U., Hjorth-Hansen, H., et al. (2017) · Blood · doi:10.1182/blood-2016-07-728873 · Cited by 154
DeRemer, D. L., Ustun, C., & Natarajan, K. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.014 · Cited by 172
Costa, D. B., Kobayashi, S., Tenen, D. G., & Huberman, M. S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.05.017 · Cited by 160
Imatinib induces hypothyroidism in patients receiving levothyroxine
DEGROOT, J., ZONNENBERG, B., PLUKKER, J., VANDERGRAAF, W., & LINKS, T. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.010 · Cited by 159
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
Sun, C., & Bernards, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.010 · Cited by 155
Luo, F. R., Yang, Z., Camuso, A., Smykla, R., McGlinchey, K., Fager, K., Flefleh, C., Castaneda, S., Inigo, I., Kan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1112 · Cited by 151
Pagano, L., Busca, A., Candoni, A., Cattaneo, C., Cesaro, S., Fanci, R., Nadali, G., Potenza, L., Russo, D., Tumbarello, M., et al. (2017) · Blood Reviews · doi:10.1016/j.blre.2016.09.002 · Cited by 148
Lei, H., Xu, H.-Z., Shan, H.-Z., Liu, M., Lu, Y., Fang, Z.-X., Jin, J., Jing, B., Xiao, X.-H., Gao, S.-M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20259-0 · Cited by 146
Kim, T., Tyndel, M. S., Kim, H. J., Ahn, J.-S., Choi, S. H., Park, H. J., Kim, Y.-K., Kim, S. Y., Lipton, J. H., Zhang, Z., et al. (2017) · Blood · doi:10.1182/blood-2016-04-708560 · Cited by 133
Cross, N. C. P., Ernst, T., Branford, S., Cayuela, J.-M., Deininger, M., Fabarius, A., Kim, D. D. H., Machova Polakova, K., Radich, J. P., Hehlmann, R., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02048-y · Cited by 120
Self-citationNicolini, F. E., Dulucq, S., Boureau, L., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Rigal-Huguet, F., Coiteux, V., Varet, B., Dubruille, V., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3373 · Cited by 111
Self-citationJabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2013) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.03.018 · Cited by 105
Self-citationImatinib-induced fatal acute liver failure
Ridruejo, E., Cacchione, R., Villamil, A. G., Marciano, S., Gadano, A. C., & Mandó, O. G. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i48.6608 · Cited by 76
Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment
Jabbour, E., Parikh, S. A., Kantarjian, H., & Cortes, J. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.09.004 · Cited by 68
Self-citationRamaraj, P., Singh, H., Niu, N., Chu, S., Holtz, M., Yee, J. K., & Bhatia, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3656 · Cited by 68
Genome Sequencing during a Patient’s Journey through Cancer
Nangalia, J., & Campbell, P. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1910138 · Cited by 66
Jeong, W., Doroshow, J. H., & Kummar, S. (2013) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2013.06.001 · Cited by 59
Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
Bidikian, A., Kantarjian, H., Jabbour, E., Short, N. J., Patel, K., Ravandi, F., Sasaki, K., & Issa, G. C. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00742-1 · Cited by 55
Self-citationComprehensive pharmacogenomic characterization of gastric cancer
Sa, J. K., Hong, J. Y., Lee, I.-K., Kim, J.-S., Sim, M.-H., Kim, H. J., An, J. Y., Sohn, T. S., Lee, J. H., Bae, J. M., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-0717-8 · Cited by 46
Rousselot, P., Mollica, L., Guilhot, J., Guerci, A., Nicolini, F. E., Etienne, G., Legros, L., Charbonnier, A., Coiteux, V., Dartigeas, C., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17654 · Cited by 46
Self-citationDeep response in multiple myeloma: a critical review.
Fulciniti, M., Munshi, N. C., & Martinez-Lopez, J. (2015) · BioMed Research International · doi:10.1155/2015/832049 · Cited by 40
Guilhot, F., Rigal-Huguet, F., Guilhot, J., Guerci-Bresler, A.-P., Maloisel, F., Rea, D., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., et al. (2021) · Leukemia · doi:10.1038/s41375-020-01117-w · Cited by 30
Self-citationNew molecular targeted therapies in thyroid cancer
Milano, A., Chiofalo, M. G., Basile, M., Salzano de Luna, A., Pezzullo, L., & Caponigro, F. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000224449.16329.c5 · Cited by 26
Gaillard, J.-B., Arnould, C., Bravo, S., Donadio, D., Exbrayat, C., Jourdan, E., Reboul, D., Chiesa, J., & Lavabre-Bertrand, T. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0595 · Cited by 23
Costa, S., Bentley, C., Regier, D. A., McTaggart-Cowan, H., Mitton, C., Burgess, M. M., & Peacock, S. J. (2019) · BMC Public Health · doi:10.1186/s12889-019-7303-2 · Cited by 22
Cortes, J. E., Lang, F., Rea, D., Hochhaus, A., Breccia, M., Goh, Y. T., Heinrich, M. C., Hughes, T. P., Janssen, J. J. W. M., le Coutre, P., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02592-9 · Cited by 16
Self-citationItonaga, H., Tsushima, H., Imanishi, D., Hata, T., Doi, Y., Mori, S., Sasaki, D., Hasegawa, H., Matsuo, E., Nakashima, J., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2013.10.022 · Cited by 12
Dominy, K. M., Claudiani, S., O’Hare, M., Szydlo, R., Gerrard, G., Foskett, P., Foroni, L., Milojkovic, D., Apperley, J. F., & Khorashad, J. (2022) · British Journal of Haematology · doi:10.1111/bjh.18026 · Cited by 11
Hamamoto, R., Koyama, T., Takahashi, S., Yasuda, T., Kobayashi, K., Akagi, Y., Kouno, N., Sudo, K., Hirata, M., Sunami, K., et al. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01781-y · Cited by 8
Metadata
- Authors
- O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., Lechner, K., Nielsen, J. L., Rousselot, P., Reiffers, J., Saglio, G., Shepherd, J., Simonsson, B., Gratwohl, A., Goldman, J. M., Kantarjian, H., Taylor, K., Verhoef, G., Bolton, A. E., Capdeville, R., & Druker, B. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-03-13
- Volume
- 348
- Issue
- 11
- Pages
- 994-1004
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2028959752
- Cited by
- 3,570
- References
- 36
- FWCI
- 106.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.